RxDoctor Payments Data

Wesley Acker, MD

Family Medicine · Rockwall, TXNPI 1134178452

Payments from drug & device makers

$10,004in general payments, 2019–2025

Across 567 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$902
  • Amgen$891
  • Lilly USA, LLC$698
  • Pfizer$679
  • AstraZeneca$672
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$9,90899%
  • Education$961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk62$1,001
GSK56$902
Amgen(2 entities)52$891
Lilly USA, LLC46$698
Pfizer40$679
AstraZeneca30$672
Abbott31$619
AbbVie(2 entities)38$607
Astellas Pharma US Inc15$372
Bayer19$345
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$261
Merck19$256
Amarin Pharma, Inc.10$192
Corcept Therapeutics5$191
Esperion Therapeutics, Inc.7$151
Boston Scientific2$144
Boehringer Ingelheim9$129
Dexcom, Inc.7$126
Optinose US, Inc.6$120
Teva Pharmaceuticals USA, Inc.7$102
Axsome Therapeutics, Inc.5$99
Johnson & Johnson6$97
Antares Pharma, Inc.6$97
Shield Therapeutics Inc2$94
Ironshore Pharmaceuticals Inc.5$76
Dynavax Technologies Corporation4$72
Verity Pharmaceuticals Inc.3$63
Sanofi Pasteur Inc.4$62
Biohaven Pharmaceutical Holding Company Ltd.4$62
Genentech USA, Inc.4$59
Sanofi-aventis U.S. LLC3$58
Biohaven Pharmaceuticals, Inc.4$57
Inspire Medical Systems, Inc.2$54
Exact Sciences3$53
Phathom Pharmaceuticals, Inc.3$44
Kowa Pharmaceuticals America, Inc.3$40
Scilex Pharmaceuticals Inc.2$38
Novartis2$36
Ironwood Pharmaceuticals, Inc2$34
Idorsia Pharmaceuticals US Inc2$32
Inari Medical, Inc.1$26
Takeda Pharmaceuticals U.S.A., Inc.4$23
ARS Pharmaceuticals Operations, Inc.1$23
Clarus Therapeutics Inc.2$22
Neos Therapeutics, LP1$22
Seqirus USA Inc1$21
Upsher-smith Laboratories LLC1$18
Almatica Pharma LLC1$17
Inogen, Inc.1$17
Tris Pharma Inc1$16
Otsuka America Pharmaceutical, Inc.1$16
Paratek Pharmaceuticals, Inc.1$15
Circassia Inc.1$15
Supernus Pharmaceuticals, Inc.1$14
Therapeuticsmd, Inc.1$14
Nalpropion Pharmaceuticals LLC1$14
Halozyme Inc1$13
Echosens North America, Inc.2$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,004 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$113,357
Medicare patients
263
Services billed
1,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin155$161,388
FarxigaDapagliflozin Propanediol55$54,505
OzempicSemaglutide39$39,778
EliquisApixaban35$31,447
JanumetSitagliptin Phos/Metformin Hcl24$25,689
MounjaroTirzepatide27$25,571
TrulicityDulaglutide19$24,048
Repatha SureclickEvolocumab31$21,191
XareltoRivaroxaban19$18,058
EntrestoSacubitril/Valsartan16$16,668
LinzessLinaclotide15$11,342
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,849
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$9,604
Breo ElliptaFluticasone/Vilanterol22$8,770
NexlizetBempedoic Acid/Ezetimibe15$8,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$129$169,048166 claims
AstraZenecaFarxiga$672$54,50555 claims
Lilly USA, LLCMounjaro, Trulicity$698$49,61946 claims
Novo NordiskOzempic$1,001$39,77839 claims
PfizerEliquis$679$31,44735 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$902$29,22355 claims
MerckJanumet$256$25,68924 claims
Johnson & JohnsonXarelto$97$18,05819 claims
NovartisEntresto$36$16,66816 claims
AbbVieLinzess, Synthroid$607$14,28766 claims
Esperion Therapeutics, Inc.Nexlizet$151$8,41015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Rockwall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →